Pliant Therapeutics Q4 net loss narrows on lower costs

Pliant Therapeutics

11/03/2026 20:36

Overview

US biopharmaceutical firm's Q4 net loss narrowed, driven by lower R&D and personnel costs

Company reported positive Phase 1 data for lead oncology program PLN-101095

Cash and short-term investments expected to fund operations into second half of 2028

Result Drivers

As of December 31, 2025, the Company had cash, cash equivalents and short-term investments of $192.4 million

LOWER R&D EXPENSES - Decrease in research and development costs driven by discontinuation of BEACON-IPF program

WORKFORCE RESTRUCTURING - Reduced general and administrative expenses due to lower personnel-related costs from strategic restructuring

Company press release: ID:nGNX5DsyPx

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$23.58 mln
Q4 Operating Expenses
-$23.58 mln
Q4 Operating Income
-$23.58 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Pliant Therapeutics Inc is $4.00, about 187.8% above its March 10 closing price of $1.39

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)